Patent ID: 7255863
Filing Date: 2007-08-14
Classification: A61K,A61P,C07K,Y10S

Abstract:
1. A method for eliciting an immune response against Group A streptococci comprising administering to a patient a pharmaceutical composition comprising (a) a recombinant fusion polypeptide wherein said recombinant fusion polypeptide comprises a multivalent immunogenic portion fused to an immunogenic polypeptide carboxy-terminal to the multivalent immunogenic portion, which protects the immunogenicity of the multivalent immunogenic portion, wherein the multivalent immunogenic portion comprises at least two immunogenic amino-terminal polypeptides of Group A streptococcal M protein from at least two different Group A streptococcal serotypes, wherein the immunogenic polypeptide carboxy-terminal to the multivalent immunogenic portion is a reiteration of the immunogenic amino-terminal polypeptide from the amino terminus of the multivalent immunogenic portion, and wherein each of the at least two immunogenic amino-terminal polypeptides is at least 10 amino acids in length, and (b) a pharmaceutically acceptable excipient, carrier, stabilizer or diluent, thereby eliciting said immune response against said Group A streptococci.